The big pharma's Research Technology Center still anticipates filing an IND before the end of 2011, but now expects it to be for "an in-house nucleic acid drug" in 2011 rather than one necessarily based on RNAi.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.